Loading...
Loading...
Response Genetics, Inc.
, a company focused on the development and sale of molecular
diagnostic tests that help determine a patient's response to cancer therapy,
today announced that it has recently executed a provider contract with Blue
Cross and Blue Shield of Illinois. Blue Cross and Blue Shield of Illinois has
7.4 million members, most of whom are located in the State of Illinois.
With the execution of this agreement, oncologists and pathologists affiliated
with this health plan now have the ability to more easily offer Response
Genetics' suite of molecular predictive testing for their patients battling
lung, colon, gastric, and melanoma cancers. Response Genetics' tests provide
treating physicians with actionable information that help enable the best
therapy to be employed for each individual patient. The personalized medicine
inherent in Response Genetics' testing services brings with it a value
proposition that is expected to improve patient outcomes and as a result
enhance efficiencies in health care delivery.
The contract with this Blue Cross Blue Shield Association affiliate
complements Response Genetics' existing managed care network and gives the
CLIA-licensed lab access to millions of additional Blue Cross Blue
Shield-insured members located primarily in Illinois and the Midwestern United
States. Blue Cross and Blue Shield of Illinois is the oldest and largest
health plan based in Illinois.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in